Influenza vaccine formulation
Executive Summary
FDA's Vaccines & Related Biological Products Advisory Committee will meet March 17 by teleconference to finalize the influenza vaccine formulation for the 2004-2005 flu season. At a Feb. 18-19 meeting, the committee recommended switching one of the two influenza A strains, and switching a Victoria lineage strain to Yamagata for the influenza B component (1"The Pink Sheet" Feb. 23, 2004, p. 32). A speakerphone will be available to the public in FDA's Building 29 B Conference Room C from 1 p.m. to 5 p.m...